TELCON RF PHARMACEUTICAL (200230) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, TELCON RF PHARMACEUTICAL (200230) reported revenue of 43.2 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202543.2 billion KRW719 million KRW-11.4 billion KRW[source]
202437.9 billion KRW-71 million KRW-26.5 billion KRW[source]
202336.3 billion KRW965 million KRW13.9 billion KRW[source]
202227.8 billion KRW-4.1 billion KRW-42.1 billion KRW[source]
202137.8 billion KRW-2.7 billion KRW-23.2 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025163.6 billion KRW47.5 billion KRW116.1 billion KRW[source]
2024172.8 billion KRW70.2 billion KRW102.6 billion KRW[source]
2023140.7 billion KRW35.1 billion KRW105.6 billion KRW[source]
2022120.0 billion KRW34.4 billion KRW85.5 billion KRW[source]
2021181.9 billion KRW60.6 billion KRW121.3 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20251.7 billion KRW-1.3 billion KRW22.5 billion KRW[source]
20241.2 billion KRW-44.1 billion KRW37.7 billion KRW[source]
2023-1.1 billion KRW-10.5 billion KRW10.4 billion KRW[source]
2022-2.1 billion KRW-7.9 billion KRW-3.4 billion KRW[source]
2021-359 million KRW879 million KRW-1.9 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice